Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer

Abstract

Treatment options for patients with advanced biliary tract cancer are limited. Dysregulation of the immune system plays an important role in the pathogenesis of biliary tract cancer (BTC). This study aimed to investigate whether tremelimumab, an anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitor, could be combined safely with microwave ablation to enhance the effect of anti-CTLA4 treatment in patients with advanced BTC. Patients were enrolled to receive monthly tremelimumab (10 mg/kg, intravenously) for six doses, followed by infusions every 3 months until off-treatment criteria were met. Thirty-six days after the first tremelimumab dose, patients underwent subtotal microwave ablation. Interval imaging studies were performed every 8 weeks. Adverse events (AEs) were noted and managed. Tumor and peripheral blood samples were collected to perform immune monitoring and whole-exome sequencing (WES). Twenty patients with refractory BTC were enrolled (median age, 56.5 years). No dose-limiting toxicities were encountered. The common treatment-related AEs included lymphopenia, diarrhea, and elevated transaminases. Among 16 patients evaluable for efficacy analysis, 2 (12.5%) patients achieved a confirmed partial response (lasting for 8.0 and 18.1 months, respectively) and 5 patients (31.3%) achieved stable disease. Median progression free survival (PFS) and overall survival (OS) were 3.4 months (95% confidence interval [CI], 2.5-5.2) and 6.0 months (95% CI, 3.8-8.8), respectively. Peripheral blood immune cell subset profiling showed increased circulating activated human leukocyte antigen, DR isotype ([HLA-DR] positive) CD8 + T cells. T-cell receptor (TCR)β screening showed tremelimumab expanded TCR repertoire, but not reaching statistical significance (P = 0.057). Conclusion: Tremelimumab in combination with tumor ablation is a potential treatment strategy for patients with advanced BTC. Increased circulating activated CD8 + T cells and TCR repertoire expansion induced by tremelimumab may contribute to treatment benefit. (Hepatology 2019;69:2048-2060).

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

“…In recent years there has been an increasing wariness that loco-therapies may eliminate not only tumors but also have additional systemic effects ( 16 , 33 ). Some studies described the immunological “abscopal effects” induced by loco-therapies and a range of cytokine and chemokine changed following various ablative procedures, suggesting that once the immune response is triggered the effects could be potentially amplified by immunotherapy ( 16 , 17 , 34 , 35 ). Our study confirmed the hypothesis and found additional ablation enhanced the antitumor effects of anti-PD-1 inhibitors and increased the response rate.…”

Overview of current targeted therapy in gallbladder cancer

“…Combined regimens of anti-PD-L1/PD-1 checkpoint agents with other therapies have also been increasingly practiced in clinic, including additional immunotherapies, chemotherapy, and targeted therapies. [254][255][256][257][258][259][260] In a phase I study led by Xie's group (NCT01853618) showed that PFS and OS were 3.4 months (95% CI 2.5-5.2) and 6.0 months (95% CI 3.8-8.8), 261 which declared that tremelimumab (anti-CTLA-4 monoclonal antibody (mAb)) is a potential treatment strategy for patients with advanced BTC. A phase I study (NCT01938612) evaluated durvalumab (anti-PD-L1 mAb) with/without tremelimumab in Asian GBC patients.…”

Immunobiology of cholangiocarcinoma

“…Although conclusions are limited from this small study, there was some correlation between markers of immune activation and clinical response (HLA-DR+). 106 Combination of immune checkpoint blockade and cytotoxic chemotherapy Chemotherapy can also increase tumour neoantigen release by direct tumour cell killing, and alters TIME through cytotoxicity of immune subsets. MDSCs can be eliminated by chemotherapy, providing a rationale for combining cytotoxic chemotherapy with ICB or other immunotherapy.…”